Approaches to implement bispecific antibody treatment of ovarian carcinoma

Cancer Immunology Immunotherapy

Volumn 45, Issue 3-4, 1997, Pages 187-189

  Canevari, Silvana ^a   Mezzanzanica, Delia ^a   Mazzoni, Alessandra ^a   Negri, Donatella R M ^a   Figini, Mariangela ^a   Ramakrishna, Venkatesh ^a   Bolis, Giorgio ^a   Colnaghi, Maria I ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

CD28 costimulation; Human antibody; Ovarian carcinoma; T cell retargeting

Indexed keywords

BISPECIFIC ANTIBODY;

ANTIBODY AFFINITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DRUG RESEARCH; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD28; ANTIGENS, CD3; CARRIER PROTEINS; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LYMPHOCYTE ACTIVATION; OVARIAN NEOPLASMS; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES;

EID: 0030829616     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050429     Document Type: Article

References (14)

1. Becker J, Pancook JD, Gillies SD, Mendelsohn J, Reisfeld RA (1996) Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci USA 93:2702
2. Botti C, Negri DRM, Seregni E, Ramakrishna V, Arienti F, Maffioli L, Lombardo C, Bogni A, Pascali C, Crippa F, Massaron S, Remonti F, Nerini-Molteni S, Canevari S, Bombardieri E (1997) Comparison of three different methods for radiolabelling human activated T-lymphocytes. Eur J Nucl Med 24:497
3. Canevari S, Mezzanzanica D, Mazzoni A, Negri DRM, Ramakrishna V, Bolhuis RLH, Colnaghi MI, Bolis G (1995) Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. J Hematother 4:423
4. Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re E, Eggermont AMM, Goey SH, Gratama JW, Lamers CHJ, Nooy MA, Parmiani G, Raspagliesi F, Ravagnani F, Scarfone G, Trimbos JB, Warnaar SO, Bolhuis RLH (1995) Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T-lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 87:1463
5. Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90:720
6. Figini M, Marks JD, Winter G, Griffiths AD (1994) In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation. J Mol Biol 239:68
7. Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR (1994) Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology 12:899
8. Mazzoni A, Mezzanzanica D, Jung G, Wolf H, Colnaghi MI, Canevari S (1996) CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatement of ovarian carcinoma. Cancer Res 56:5443
9. Mezzanzanica D, Garrido MA, Neblock DS, Daddona PE, Andrew SM, Zurawski VR Jr, Segal DM, Wunderlich JR (1991) Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab′)2 antibody prolong host survival in a murine xenograft model. Cancer Res 51:5716
10. Miotti S, Canevari S, Ménard S, Mezzanzanica D, Porro G, Pupa SM, Regazzoni M, Tagliabue E, Colnaghi MI (1987) Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 39:297
11. Negri DRM, Tosi E, Valota O, Ferrini S, Cambiaggi A, Sforzini S, Silvani A, Ruffini PA, Colnaghi MI, Canevari S (1995) In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab′)2 bispecific monoclonal antibody. Br J Cancer 72:928
12. Renner C, Pfreundschuh M (1995) Tumor therapy by immune recruitment with bispecific antibodies. Immunol Rev 145:179
13. HER2 and growth inhibition of cells with HER2/neu gene amplification. Int J Cancer 47:933
14. Tosi E, Valota O, Negri DRM, Adobati E, Mazzoni A, Meazza R, Ferrini S, Colnaghi MI, Canevari S (1995) Anti-tumor efficacy of an anti-epidermal growth factor receptor monoclonal antibody and its F(ab′)2 fragment against high- and low-EGFR-expressing carcinomas in nude mice. Int J Cancer 62:643